$NBIX
NEUROCRINE BIOSCIENCES INC

2016 Q3 Form 10-Q Financial Statement

#000119312516670128 Filed on August 03, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2016 Q2 2015 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $0.00
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $17.49M $14.97M $6.600M
YoY Change 52.12% 126.74% 57.14%
% of Gross Profit
Research & Development $20.94M $26.86M $18.72M
YoY Change -14.13% 43.51% 84.22%
% of Gross Profit
Depreciation & Amortization $400.0K $300.0K $300.0K
YoY Change 100.0% 0.0% 50.0%
% of Gross Profit
Operating Expenses $38.44M $41.83M $25.32M
YoY Change 7.23% 65.18% 76.32%
Operating Profit -$38.44M -$41.83M -$25.32M
YoY Change 7.23% 65.18% 76.32%
Interest Expense $0.00 $0.00 $500.0K
YoY Change -100.0% -100.0% 150.0%
% of Operating Profit
Other Income/Expense, Net $1.549M $1.548M $1.335M
YoY Change 9.94% 15.96% 36.22%
Pretax Income -$36.90M -$40.30M -$24.00M
YoY Change 7.27% 67.92% 79.1%
Income Tax
% Of Pretax Income
Net Earnings -$36.89M -$40.28M -$23.99M
YoY Change 7.12% 67.92% 79.26%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$425.1K -$464.8K -$280.7K
COMMON SHARES
Basic Shares Outstanding 86.75M shares 86.66M shares 85.42M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $353.0M $387.4M $384.7M
YoY Change -6.32% 0.7% 97.59%
Cash & Equivalents $99.76M $86.25M $132.1M
Short-Term Investments $253.3M $301.2M $252.7M
Other Short-Term Assets $4.849M $4.568M $4.696M
YoY Change -18.37% -2.73%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $357.9M $392.0M $389.4M
YoY Change -6.5% 0.65% 97.1%
LONG-TERM ASSETS
Property, Plant & Equipment $6.180M $5.811M $2.802M
YoY Change 115.03% 107.39% 25.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $30.20M $27.20M $114.2M
YoY Change -70.39% -76.18% 74.89%
Other Assets $4.900M $4.900M $4.800M
YoY Change 2.08% 2.08% 9.09%
Total Long-Term Assets $41.27M $37.87M $121.8M
YoY Change -62.36% -68.9% 69.24%
TOTAL ASSETS
Total Short-Term Assets $357.9M $392.0M $389.4M
Total Long-Term Assets $41.27M $37.87M $121.8M
Total Assets $399.2M $429.8M $511.2M
YoY Change -18.94% -15.92% 89.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.719M $1.762M $1.035M
YoY Change 43.61% 70.24% 22.34%
Accrued Expenses $20.75M $21.02M $12.39M
YoY Change 42.99% 69.6% 66.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $26.67M $26.90M $17.55M
YoY Change 34.53% 53.24% 45.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $113.0K $113.0K $245.0K
YoY Change -48.64% -53.88% -5.77%
Total Long-Term Liabilities $113.0K $113.0K $245.0K
YoY Change -48.64% -53.88% -5.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.67M $26.90M $17.55M
Total Long-Term Liabilities $113.0K $113.0K $245.0K
Total Liabilities $47.51M $48.80M $44.27M
YoY Change 4.43% 10.25% 35.39%
SHAREHOLDERS EQUITY
Retained Earnings -$1.012B -$974.8M -$851.5M
YoY Change 14.19% 14.48% 7.65%
Common Stock $1.364B $1.356B $86.00K
YoY Change 2.25% 1576475.58% 13.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $351.7M $381.0M $466.9M
YoY Change
Total Liabilities & Shareholders Equity $399.2M $429.8M $511.2M
YoY Change -18.94% -15.92% 89.66%

Cashflow Statement

Concept 2016 Q3 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$36.89M -$40.28M -$23.99M
YoY Change 7.12% 67.92% 79.26%
Depreciation, Depletion And Amortization $400.0K $300.0K $300.0K
YoY Change 100.0% 0.0% 50.0%
Cash From Operating Activities -$31.10M -$14.30M $14.00M
YoY Change 67.2% -202.14% -241.41%
INVESTING ACTIVITIES
Capital Expenditures -$800.0K -$2.300M -$500.0K
YoY Change 166.67% 360.0% -16.67%
Acquisitions
YoY Change
Other Investing Activities $44.00M -$13.40M -$53.40M
YoY Change -192.44% -74.91% -7.45%
Cash From Investing Activities $43.20M -$15.70M -$53.90M
YoY Change -190.19% -70.87% -7.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.300M 900.0K 1.800M
YoY Change 85.71% -50.0% 500.0%
NET CHANGE
Cash From Operating Activities -31.10M -14.30M 14.00M
Cash From Investing Activities 43.20M -15.70M -53.90M
Cash From Financing Activities 1.300M 900.0K 1.800M
Net Change In Cash 13.40M -29.10M -38.10M
YoY Change -120.36% -23.62% -43.97%
FREE CASH FLOW
Cash From Operating Activities -$31.10M -$14.30M $14.00M
Capital Expenditures -$800.0K -$2.300M -$500.0K
Free Cash Flow -$30.30M -$12.00M $14.50M
YoY Change 65.57% -182.76% -255.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
86751633 shares
CY2008Q4 us-gaap Sale Leaseback Transaction Deferred Gain Net
SaleLeasebackTransactionDeferredGainNet
39100000
CY2015Q1 nbix Cease Use Liability
CeaseUseLiability
2565000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
132070000
CY2015Q2 nbix Cease Use Liability
CeaseUseLiability
2326000
CY2016Q1 nbix Cease Use Liability
CeaseUseLiability
1043000
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000 shares
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86751633 shares
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86751633 shares
CY2016Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
26899000
CY2016Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
10231000
CY2016Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21017000
CY2016Q2 us-gaap Liabilities
Liabilities
48800000
CY2016Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
386000
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
87000
CY2016Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1355768000
CY2016Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
113000
CY2016Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-39000
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-974778000
CY2016Q2 us-gaap Sale Leaseback Transaction Deferred Gain Net
SaleLeasebackTransactionDeferredGainNet
12600000
CY2016Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1704000
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
381038000
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86246000
CY2016Q2 us-gaap Assets
Assets
429838000
CY2016Q2 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
27178000
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
429838000
CY2016Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1762000
CY2016Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
328330000
CY2016Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4883000
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5811000
CY2016Q2 us-gaap Assets Current
AssetsCurrent
391966000
CY2016Q2 us-gaap Other Assets Current
OtherAssetsCurrent
4568000
CY2016Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
197453000
CY2016Q2 us-gaap Investments
Investments
328300000
CY2016Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
89000
CY2016Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
36000
CY2016Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
40022000
CY2016Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
125000
CY2016Q2 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
301152000
CY2016Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
157431000
CY2016Q2 nbix Number Of Renewal Options
NumberOfRenewalOptions
2 RenewalOptions
CY2016Q2 nbix Letters Of Credit Collateral
LettersOfCreditCollateral
4600000
CY2016Q2 nbix Cease Use Liability
CeaseUseLiability
972000
CY2016Q2 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
9140000
CY2016Q2 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
713000
CY2016Q2 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
259000
CY2016Q2 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
3475000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31014000
CY2014Q4 nbix Cease Use Liability
CeaseUseLiability
2678000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86262594 shares
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86262594 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25715000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
10231000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19034000
CY2015Q4 us-gaap Liabilities
Liabilities
50331000
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
269000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
86000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1340579000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-977000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
221000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-915234000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1711000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
22000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
358549000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
5521000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
424454000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
474785000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2561000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
387484000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4791000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3432000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
384074000
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
4883000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
364070000
CY2015Q4 us-gaap Investments
Investments
387500000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
959000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74195000
CY2015Q4 us-gaap Assets
Assets
474785000
CY2015Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
82488000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
981000
CY2015Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
304996000
CY2015Q4 nbix Cease Use Liability
CeaseUseLiability
1983000
CY2015Q4 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
10898000
CY2015Q4 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
1555000
CY2015Q4 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
428000
CY2015Q4 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
3423000
us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
200000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1000000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
4000000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
300000 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4222000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1100000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
82947000 shares
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25306000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
790000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2579000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
1668000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
286860000
us-gaap Licenses Revenue
LicensesRevenue
19769000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27610000
us-gaap Revenues
Revenues
19769000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
302000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-16000
us-gaap Investment Income Net
InvestmentIncomeNet
763000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2431000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35294000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-15000
nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
1659000
us-gaap Net Income Loss
NetIncomeLoss
-25179000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-127000
us-gaap Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
1700000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
275284000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
495000
us-gaap Operating Expenses
OperatingExpenses
47379000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
275284000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
53000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12085000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
10231000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
9000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1673000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
101056000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8300000
us-gaap Share Based Compensation
ShareBasedCompensation
8263000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
117619000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-170006000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4600000
nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
265000
nbix Increase Decrease In Cease Use Expense
IncreaseDecreaseInCeaseUseExpense
0
nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-352000
nbix Change In Estimate On Cease Use Liability
ChangeInEstimateOnCeaseUseLiability
-87000
nbix Nonoperating Gain Loss On Disposition Of Assets
NonoperatingGainLossOnDispositionOfAssets
9000
dei Document Type
DocumentType
10-Q
dei Trading Symbol
TradingSymbol
NBIX
us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
300000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
900000 shares
dei Entity Central Index Key
EntityCentralIndexKey
0000914475
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3700000 shares
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
300000 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-43546000
dei Amendment Flag
AmendmentFlag
false
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
200000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
us-gaap Property Management Fee Percent Fee
PropertyManagementFeePercentFee
0.035 pure
dei Entity Registrant Name
EntityRegistrantName
NEUROCRINE BIOSCIENCES INC
us-gaap Use Of Estimates
UseOfEstimates
<div><em><font size="2">Use of Estimates</font></em>. The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86595000 shares
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-58606000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2984000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2440000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
1724000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
169488000
us-gaap Licenses Revenue
LicensesRevenue
15000000
us-gaap Operating Income Loss
OperatingIncomeLoss
-62685000
us-gaap Revenues
Revenues
15000000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-315000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
92000
us-gaap Investment Income Net
InvestmentIncomeNet
1417000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3141000
us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
600000
us-gaap Net Income Loss
NetIncomeLoss
-59544000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
938000
us-gaap Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
1700000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
998000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
us-gaap Operating Expenses
OperatingExpenses
77685000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
998000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-136000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26919000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
13000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1184000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
12051000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14200000
us-gaap Share Based Compensation
ShareBasedCompensation
14192000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
227150000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
54599000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50766000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-108000
nbix Lease Extension Period
LeaseExtensionPeriod
P10Y
nbix Subleased Agreement Area
SubleasedAgreementArea
16000 sqft
nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
1707000
nbix Lease Expiration Year
LeaseExpirationYear
2019
nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
181000
nbix Increase Decrease In Cease Use Expense
IncreaseDecreaseInCeaseUseExpense
-584000
nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-181000
nbix Change In Estimate On Cease Use Liability
ChangeInEstimateOnCeaseUseLiability
-830000
nbix Nonoperating Gain Loss On Disposition Of Assets
NonoperatingGainLossOnDispositionOfAssets
17000
CY2007Q4 us-gaap Mortgage Loans On Real Estate Cost Of Mortgages Sold
MortgageLoansOnRealEstateCostOfMortgagesSold
47700000
CY2007Q4 us-gaap Sale Leaseback Transaction Net Proceeds Financing Activities
SaleLeasebackTransactionNetProceedsFinancingActivities
61000000
CY2007Q4 us-gaap Sale Leaseback Transaction Gross Proceeds Investing Activities
SaleLeasebackTransactionGrossProceedsInvestingActivities
109000000
CY2007Q4 nbix Sale Leaseback Transaction Lease Period
SaleLeasebackTransactionLeasePeriod
P12Y
CY2007Q4 nbix Number Of Buildings Leased
NumberOfBuildingsLeased
2 Building
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
270700000
CY2015Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
4100000 shares
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
200000 shares
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
85518000 shares
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24212000
CY2015Q2 us-gaap Licenses Revenue
LicensesRevenue
0
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-25322000
CY2015Q2 us-gaap Revenues
Revenues
0
CY2015Q2 us-gaap Investment Income Net
InvestmentIncomeNet
506000
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1335000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-23987000
CY2015Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-225000
CY2015Q2 us-gaap Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
800000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
25322000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6603000
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4700000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18719000
CY2015Q2 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
829000
CY2015Q2 nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
152000
CY2015Q2 nbix Change In Estimate On Cease Use Liability
ChangeInEstimateOnCeaseUseLiability
-87000
CY2015Q2 nbix Nonoperating Gain Loss On Disposition Of Assets
NonoperatingGainLossOnDispositionOfAssets
0
CY2016Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3800000 shares
CY2016Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
300000 shares
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.46
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86694000 shares
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40131000
CY2016Q2 us-gaap Licenses Revenue
LicensesRevenue
0
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-41828000
CY2016Q2 us-gaap Revenues
Revenues
0
CY2016Q2 us-gaap Investment Income Net
InvestmentIncomeNet
680000
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1548000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-40280000
CY2016Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
149000
CY2016Q2 us-gaap Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
900000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
41828000
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14965000
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7300000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26863000
CY2016Q2 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
854000
CY2016Q2 nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
71000
CY2016Q2 nbix Change In Estimate On Cease Use Liability
ChangeInEstimateOnCeaseUseLiability
0
CY2016Q2 nbix Nonoperating Gain Loss On Disposition Of Assets
NonoperatingGainLossOnDispositionOfAssets
14000

Files In Submission

Name View Source Status
0001193125-16-670128-index-headers.html Edgar Link pending
0001193125-16-670128-index.html Edgar Link pending
0001193125-16-670128.txt Edgar Link pending
0001193125-16-670128-xbrl.zip Edgar Link pending
d386773d10q.htm Edgar Link pending
d386773dex311.htm Edgar Link pending
d386773dex312.htm Edgar Link pending
d386773dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
nbix-20160630.xml Edgar Link completed
nbix-20160630.xsd Edgar Link pending
nbix-20160630_cal.xml Edgar Link unprocessable
nbix-20160630_def.xml Edgar Link unprocessable
nbix-20160630_lab.xml Edgar Link unprocessable
nbix-20160630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending